Founded in 2001, Fusion Antibodies is a leading Contract Research Organisation (CRO) headquartered in Belfast, Northern Ireland. With over two decades of expertise, the company provides a comprehensive suite of antibody development capabilities spanning discovery, development, and supply.

Fusion developed proprietary best-in-class platforms such as Optimal® Mammalian Display and AI/ML-ab™ for antibody discovery, CDRx® for antibody humanization, RAMP® for affinity maturation, and Ab-ility™ for in silico developability assessment.

The company's mission is to enable biopharmaceutical and diagnostic organisations to develop innovative products in a timely, cost-effective manner, working as a true extension of client teams to deliver solutions that meet both scientific and commercial goals.